Novavax: Influenza, Human trials

The registry lists 19 Influenza, Human studies with Novavax as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 7Phase 2 13Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 3 Pivotal Trial of NanoFlu™ in Older AdultsCompletedNCT04120194Phase 3Results posted
• Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older AdultsTerminatedNCT03658629Phase 2Results posted
• Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)CompletedNCT03293498Phase 1/2Results posted
• Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza VaccineWithdrawnNCT06485752Phase 2/3
• Lot Consistency Study of COVID-19 and Influenza Combination VaccineWithdrawnNCT06482359Phase 2/3
• A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination VaccineCompletedNCT06291857Phase 3
• A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination VaccineCompletedNCT05519839Phase 2
• Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young AdultsCompletedNCT02307851Phase 2
• A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ AdjuvantCompletedNCT02078674Phase 1/2
• A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1CompletedNCT01897701Phase 1
• A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2CompletedNCT01596725Phase 1
• A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1CompletedNCT01594320Phase 1
• A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young AdultsCompletedNCT01561768Phase 2
• Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly VolunteersStatus unknownNCT01444482Phase 1
• Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) VaccineCompletedNCT01072799Phase 2
• Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older AdultsCompletedNCT01014806Phase 2
• Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)CompletedNCT00903552Phase 2
• Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy AdultsCompletedNCT00754455Phase 2
• Safety, Reactogenicity and Immunogenicity of an H5N1 VLPCompletedNCT00519389Phase 1/2